quinoline/seizures

This invention relates to a class of 3,5-dihydro-1H-pyrazolo[3,4-c]quinoline-1,4(2H)-dione derivatives which are substituted in the 2-position by an optionally substituted phenyl moiety. These compounds are selective non-competitive antagonists of N-methyl-Disparate (NMDA) receptors. More

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is to imidazo[1,5-a]quinolines which are useful pharmaceutical agents for the treatment of anxiety, sleep disorders, panic states, convulsions and muscle disorders. 2. Description of the Related Art EP 283,162 discloses

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to heterocyclic derivatives, especially quinoline carbonyl pyrrolidines that bind with high selectivity and high affinity to the benzodiazepine site of GABA.sub.A receptors. This invention also relates to pharmaceutical

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to 4-oxo-quinoline-3-carboxamides and more specifically to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABA.sub.A receptors. This invention also relates to pharmaceutical

FIELD OF THE INVENTION This invention relates to substituted fused pyrazolecarboxylic acid arylamides and related compounds, such as substituted fused pyrazolecarboxylic acid arylamides that bind with high selectivity and high affinity to the benzodiazepine site of GABA.sub.A receptors. This

BACKGROUND OF THE INVENTION The present invention relates to a agents useful as excitatory amino acid antagonists. The quinoline and kynurenin derivatives of the present invention have affinity for the glycine binding site of the NMDA receptor. Compounds of the present invention should be usable for